文献速递妇产影像儿科影像US

早孕期超声筛查与产前检测的要点与陷阱:图解综述

Pearls and Pitfalls of First-Trimester US Screening and Prenatal Testing: A Pictorial Review.
PubMed 文献 · Radiographics · 2025-01-01

本文以图解形式综述早孕期超声筛查与产前检测的要点与陷阱,纳入2024年超声放射医师学会共识会议提出的早孕期术语,强调早孕期超声用于确认妊娠位置、数目和孕龄,并介绍11周至13周6天胎儿解剖评估可检出40%-70%的结构异常或非整倍体相关异常;所有患者不论年龄或基线风险均应接受染色体异常筛查与诊断检测,无创产前检测是常见胎儿非整倍体最敏感特异的筛查但不等同于诊断检测。

要点

  • 早孕期超声确认妊娠位置、数目和孕龄,2024年超声放射医师学会共识会议提出早孕期术语以强调清晰简洁用语。
  • 11周至13周6天系统评估胎儿解剖可检出40%-70%的异常,但不能替代中孕期解剖检查。
  • 颈项透明层增厚是早孕期最常见异常;筛查阳性、颈项透明层增厚或其他超声异常应提示遗传咨询并以诊断检测确认。

核心结论

  • 早孕期超声用于确认妊娠位置、数目和孕龄;11周至13周6天系统评估胎儿解剖可检出40%-70%的异常,但不能替代中孕期解剖检查;所有患者不论年龄或基线风险均应接受染色体异常筛查与诊断检测;无创产前检测是常见胎儿非整倍体最敏感特异的筛查但不等同于诊断检测;筛查阳性、颈项透明层增厚或其他超声异常应提示遗传咨询并以诊断检测确认,早期发现非整倍体和结构异常有助于咨询和妊娠管理决策。

研究设计与样本

  • 图解综述,纳入2024年超声放射医师学会(Society of Radiologists in Ultrasound)共识会议提出的早孕期术语并予以整合和重点展示。

关键影像表现/征象

  • 颈项透明层增厚是早孕期最常见的异常。
  • 11周至13周6天系统评估胎儿解剖可检出40%-70%的结构异常或非整倍体相关异常。

诊断标准与关键数值

  • 无创产前检测通过检测胎儿游离DNA可在早孕期进行,是常见胎儿非整倍体最敏感特异的筛查,但不等同于诊断检测。
  • 血清母体生物标志物分析联合颈项透明层测量可用于计算常见三体的风险估计。
  • 筛查阳性、颈项透明层增厚或其他超声异常应以诊断检测(绒毛膜绒毛取样或羊膜腔穿刺)确认。

临床应用与阅片要点

  • 所有患者不论年龄或基线风险均应接受染色体异常筛查与诊断检测。
  • 筛查阳性、颈项透明层增厚或其他超声异常应提示遗传咨询并以诊断检测确认。
  • 早孕期解剖评估不能替代中孕期解剖检查。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

First-trimester US is imperative in evaluation of early pregnancy to confirm pregnancy location and number and gestational age. The 2024 Society of Radiologists in Ultrasound consensus conference established a first-trimester lexicon to highlight the importance of clear and concise language, which is incorporated and featured by the authors. With improved technologies and understanding of fetal development, first-trimester anatomic studies, between 11 weeks and 13 weeks 6 days gestation, are becoming more frequently used. While not a replacement for the second-trimester anatomic study, systematic evaluation of fetal anatomy at this early gestational age allows detection of 40%-70% of anomalies, whether structural or related to aneuploidy. All patients, regardless of age or baseline risk, should be offered screening and diagnostic testing for chromosomal abnormalities. A variety of prenatal screening approaches are available, each with strengths and limitations. Noninvasive prenatal testing with detection of fetal cell-free DNA can be performed in the first trimester and is the most sensitive and specific screening for the common fetal aneuploidies, but is not equivalent to diagnostic testing. Alternatively, serum analytes for maternal biomarkers in conjunction with nuchal translucency (NT) measurement can be used to calculate a risk estimate for common trisomies. Increased NT is the most common abnormality seen in the first trimester. Positive screening results, increased NT, or other anomaly at US should prompt genetic counseling and be confirmed with diagnostic testing (chorionic villus sampling or amniocentesis). Early detection of aneuploidy and structural anomalies allows counseling and informs decisions for pregnancy management. ©RSNA, 2025 Supplemental material is available for this article.

来源:Radiographics,查看原文。版权归原作者所有。

引用

  1. Packard AT, Clingan MJ, Strachowski LM, et al. Pearls and Pitfalls of First-Trimester US Screening and Prenatal Testing: A Pictorial Review. Radiographics. 2025. PMID: 40372936. doi:10.1148/rg.240184

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。